Monday, March 27, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Biodetection

New BARDA-Funded Influenza Diagnostic Launched

by Global Biodefense Staff
October 10, 2012

Collaborators Focus Diagnostics, maker of the Simplexa brand of molecular test kits, and 3M, maker of the 3M Integrated Cycler technology, have received U.S. Food and Drug Administration (FDA) 510(k) clearance and CLIA moderate-complexity categorization for an influenza diagnostic developed through funding by the U.S. Department of Health and Human Services BARDA BAA program for public health preparedness.

The Simplexa Flu A/B & RSV Direct test on the 3M™ Integrated Cycler aids in the qualitative detection and differentiation of RNA of influenza A and B viruses and respiratory syncytial virus (RSV), common causes of respiratory illness. The collaboration, formed in 2009, has produced several Simplexa molecular tests, including the first FDA-cleared commercial test for the influenza A H1N1 (2009) virus.

The assay is the first ‘moderate-complexity’ molecular test from the Focus Diagnostics’ Simplexa product line. Moderate complexity laboratories include certain types of physician’s offices, community hospitals, health clinics and integrated delivery networks. These facilities typically lack the personnel and technology to perform high-complexity molecular diagnostic tests.  Since the test can be performed in these moderate complexity labs, patient results may be obtained readily to help speed therapeutic decisions.

“The future of influenza and all respiratory virus testing is molecular diagnostics, given its potential for high sensitivity and fast reporting of test results, which are essential for patient management,” said Jay M. Lieberman, M.D., medical director, infectious diseases, for Focus Diagnostics and parent company Quest Diagnostics. “The clearance and moderate complexity categorization of the Simplexa test on the 3M Integrated Cycler signifies an important step forward in expanding access to near-patient molecular testing, potentially helping clinicians to make better decisions for their patients.”

The new Simplexa test was developed in part with $5.9 million in funding from The Biomedical Advanced Research and Development Authority (BARDA) under Contract No. HHSO100201000049C.

Tags: ASPRAwardsBARDAH1N1HHSInfluenza

Related Posts

small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
DoD Awards ENA Respiratory $4.38M for Broad-Spectrum Antiviral Development
Industry News

DoD Awards ENA Respiratory $4.38M for Broad-Spectrum Antiviral Development

January 10, 2023
New Material Helps Train First Responders on Biothreats
Biodetection

New Material Helps Train First Responders on Biothreats

January 4, 2023
Much of the CDC is Working Remotely. That Could Make Changing the Agency Difficult.
Policy + Initiatives

Much of the CDC is Working Remotely. That Could Make Changing the Agency Difficult.

December 7, 2022
Load More

Latest News

Biodefense Headlines – 26 March 2023

March 26, 2023
Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC